Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10524563rdf:typepubmed:Citationlld:pubmed
pubmed-article:10524563lifeskim:mentionsumls-concept:C1522496lld:lifeskim
pubmed-article:10524563lifeskim:mentionsumls-concept:C0086582lld:lifeskim
pubmed-article:10524563lifeskim:mentionsumls-concept:C0549193lld:lifeskim
pubmed-article:10524563lifeskim:mentionsumls-concept:C1519232lld:lifeskim
pubmed-article:10524563pubmed:issue9lld:pubmed
pubmed-article:10524563pubmed:dateCreated1999-11-30lld:pubmed
pubmed-article:10524563pubmed:abstractTextInformation on the effect of abnormal thyroid function on male reproduction is less available than that for the female. To assess the effects of hyperthyroidism on hypothalamic-pituitary-testicular axis and on spermogram parameters, 25 male patients (19-47 years old) suffering from active Graves' disease were studied. Serum luteinizing hormone (LH), follicle stimulating hormone (FSH), and prolactin (PRL) were measured before and after administration of 100 microg GnRH plus 200 microg thyrotropin-releasing hormone (TRH). Testosterone (T), estradiol (E2), and 17-hydroxyprogesterone (17-OHP) were determined before and after 5000 IU human chorionic gonadotropin (HCG) administration. Serum sex hormone-binding globulin (SHBG), cortisol-binding globulin (CBG), androstenedione and bioavailable testosterone (bioT), and bioavailable estradiol (bioE2) were also measured. Spermograms according to World Health Organization (WHO) criteria were determined in 21 patients. Hormonal and seminal studies were repeated in six patients after 7 to 19 months of euthyroidism achieved after treatment for hyperthyroidism. As a control group, 10 normal men were evaluated. Impaired sexual function, gynecomastia, and low testicular volume were found in 12, 6, and 3 hyperthyroid patients. Mean basal LH was significantly higher than the control group (7.8 +/- 4.7 vs. 5.0 +/- 1.9 mIU/mL, respectively, p < 0.02), with hyperresponse to GnRH. The response of PRL to TRH was lower in patients versus control group (30 minutes: 3.9 +/- 3.4 and 12.0 +/- 2.8 ng/mL, p < 0.01). Basal levels of steroids and SHBG were significantly higher in patients than in normal men (T: 9.3 +/- 3.3 vs. 5.4 +/- 1.6 ng/mL, p < 0.005; E2: 62.2 +/- 25.2 vs. 32.1 +/- 11.0 pg/mL, p < 0.005; 17-OHP: 2.4 +/- 0.9 vs. 1.1 +/- 0.5 ng/mL, p < 0.001; SHBG: 102.3 +/- 37.3 vs. 19.0 +/- 5.0 nmol/L, p < 0.01). The maximal increment of T and 17-OHP after HCG was lower in hyperthyroid patients than in normal men (p < 0.019 and p < 0.001, respectively). Basal bioT was lower in patients than controls (1.7 +/- 0.8 and 3.1 +/- 1.9 ng/mL, p < 0.02). The following incidence of abnormal semen parameters was found: asthenospermia 85.7%, hypospermia 61.9%, oligospermia 42.9%, necrospermia 42.9% and teratospermia 19.0%. In euthyroidism, a normalization of 85% of seminal alterations was observed in the limited number of patients evaluated. Our results confirm that hyperthyroidism causes marked alterations of the gonadotropic and PRL axis and dramatically affects spermatic function. BioT measurement was useful to identify hypoandrogenism in these patients in spite of the high concentration of total testosterone. The restoration of most semen parameters when euthyroidism was achieved suggests that the alterations were induced by the Graves' disease.lld:pubmed
pubmed-article:10524563pubmed:languageenglld:pubmed
pubmed-article:10524563pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10524563pubmed:citationSubsetIMlld:pubmed
pubmed-article:10524563pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10524563pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10524563pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10524563pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10524563pubmed:statusMEDLINElld:pubmed
pubmed-article:10524563pubmed:monthSeplld:pubmed
pubmed-article:10524563pubmed:issn1050-7256lld:pubmed
pubmed-article:10524563pubmed:authorpubmed-author:ArandaCClld:pubmed
pubmed-article:10524563pubmed:authorpubmed-author:ScagliaHHlld:pubmed
pubmed-article:10524563pubmed:authorpubmed-author:ZylberszteinC...lld:pubmed
pubmed-article:10524563pubmed:authorpubmed-author:LevalleOOlld:pubmed
pubmed-article:10524563pubmed:authorpubmed-author:HermesRRlld:pubmed
pubmed-article:10524563pubmed:authorpubmed-author:OnetoAAlld:pubmed
pubmed-article:10524563pubmed:authorpubmed-author:GutierrezSSlld:pubmed
pubmed-article:10524563pubmed:authorpubmed-author:AquilanoDDlld:pubmed
pubmed-article:10524563pubmed:authorpubmed-author:AbalovichMMlld:pubmed
pubmed-article:10524563pubmed:issnTypePrintlld:pubmed
pubmed-article:10524563pubmed:volume9lld:pubmed
pubmed-article:10524563pubmed:ownerNLMlld:pubmed
pubmed-article:10524563pubmed:authorsCompleteYlld:pubmed
pubmed-article:10524563pubmed:pagination857-63lld:pubmed
pubmed-article:10524563pubmed:dateRevised2005-11-17lld:pubmed
pubmed-article:10524563pubmed:meshHeadingpubmed-meshheading:10524563...lld:pubmed
pubmed-article:10524563pubmed:meshHeadingpubmed-meshheading:10524563...lld:pubmed
pubmed-article:10524563pubmed:meshHeadingpubmed-meshheading:10524563...lld:pubmed
pubmed-article:10524563pubmed:meshHeadingpubmed-meshheading:10524563...lld:pubmed
pubmed-article:10524563pubmed:meshHeadingpubmed-meshheading:10524563...lld:pubmed
pubmed-article:10524563pubmed:meshHeadingpubmed-meshheading:10524563...lld:pubmed
pubmed-article:10524563pubmed:meshHeadingpubmed-meshheading:10524563...lld:pubmed
pubmed-article:10524563pubmed:meshHeadingpubmed-meshheading:10524563...lld:pubmed
pubmed-article:10524563pubmed:meshHeadingpubmed-meshheading:10524563...lld:pubmed
pubmed-article:10524563pubmed:meshHeadingpubmed-meshheading:10524563...lld:pubmed
pubmed-article:10524563pubmed:meshHeadingpubmed-meshheading:10524563...lld:pubmed
pubmed-article:10524563pubmed:meshHeadingpubmed-meshheading:10524563...lld:pubmed
pubmed-article:10524563pubmed:meshHeadingpubmed-meshheading:10524563...lld:pubmed
pubmed-article:10524563pubmed:meshHeadingpubmed-meshheading:10524563...lld:pubmed
pubmed-article:10524563pubmed:meshHeadingpubmed-meshheading:10524563...lld:pubmed
pubmed-article:10524563pubmed:meshHeadingpubmed-meshheading:10524563...lld:pubmed
pubmed-article:10524563pubmed:meshHeadingpubmed-meshheading:10524563...lld:pubmed
pubmed-article:10524563pubmed:meshHeadingpubmed-meshheading:10524563...lld:pubmed
pubmed-article:10524563pubmed:year1999lld:pubmed
pubmed-article:10524563pubmed:articleTitleHypothalamic-pituitary-testicular axis and seminal parameters in hyperthyroid males.lld:pubmed
pubmed-article:10524563pubmed:affiliationDivisión Endocrinology, Hospital Carlos Durand, Buenos Aires, Argentina. levalle@pure.com.arlld:pubmed
pubmed-article:10524563pubmed:publicationTypeJournal Articlelld:pubmed